The study, led by academics from Leeds University, assessed the treatment of people with indeterminate pulmonary nodules (IPNs).
It looked at the deployment of the £70 Oncimmune blood test in combination with computed tomography and compared it with using the CT scans on their own.
Not only did the approach have a “positive impact on the outcomes of those patients observed”, but it also provided a cost-effective method of managing patients.
Researchers calculated the incremental cost-effectiveness ratio to be £2,417, substantially below the accepted £20,000 per quality-adjusted life-year threshold set by the National Institute for Health and Care Excellence (NICE).
Oncimmune chief executive Adam Hill lauded the work of the Leeds University Academic Unit of Health Economics, which was supported by the NIHR Leeds In Vitro Diagnostics Co-operative, adding he was “very pleased” with the results.
“This study has enabled the generation of further data for the EarlyCDT Lung blood test that supports its adoption in ongoing discussions with healthcare providers across the UK," he added in a statement.
The research was published PLOS ONE, a site for peer-reviewed academic research.